Rockwell Medical, Inc.
RMTINasdaqCIK 1041024HealthcareFiscal year ends Dec 31
Reports and events: 379 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-1311:27 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-056470 |
| 2026-08-1310:59 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001628280-26-056461 |
| 2026-08-1310:14 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-056454 |
| 2026-07-2010:22 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-048752 |
| 2026-06-2910:17 ET | 8-K | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001628280-26-045866 |
| 2026-06-1520:27 ET | 8-K | 5.07 Shareholder vote results | 0001628280-26-043210 |
| 2026-05-0821:00 ET | 8-K | 3.01 Delisting notice | 0001628280-26-032987 |
| 2026-05-0711:14 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-031680 |
| 2026-05-0710:59 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001628280-26-031663 |
| 2026-05-0710:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-031629 |
| 2026-04-3010:59 ET | DEF 14A | Proxy statementPeriod 2026-04-30 | 0001628280-26-028571 |
| 2026-03-2611:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-021195 |
| 2026-03-2611:01 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001628280-26-021186 |
| 2026-03-2610:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-021176 |
| 2026-01-2011:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-002478 |
| 2026-01-0511:33 ET | 8-K | 8.01 Other events | 0001628280-26-000221 |
| 2025-11-1812:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-25-113452 |
| 2025-11-1212:21 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-051311 |
| 2025-11-1212:05 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001628280-25-051290 |
| 2025-11-1211:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-051267 |
| 2025-09-2920:32 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-25-094524 |
| 2025-08-1411:05 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001041024-25-000011 |
| 2025-08-1410:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001041024-25-000009 |
| 2025-05-2020:13 ET | 8-K | 5.07 Shareholder vote results | 0001104659-25-050997 |
| 2025-05-1211:21 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-024444 |
| 2025-05-1211:00 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001628280-25-024434 |
| 2025-05-1210:18 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-046957 |
| 2025-04-1410:30 ET | DEF 14A | Proxy statementPeriod 2025-05-20 | 0001140361-25-013599 |
| 2025-03-2013:13 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-014017 |
| 2025-03-2011:01 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001628280-25-013983 |
| 2025-03-2010:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-025782 |
| 2024-12-1221:58 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-24-128064 |
| 2024-11-1316:41 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-117447 |
| 2024-11-1212:10 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001628280-24-046839 |
| 2024-11-1212:03 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-24-046835 |
| 2024-11-1211:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-046792 |
| 2024-08-0820:51 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-24-036211 |
| 2024-08-0811:00 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001628280-24-035859 |
| 2024-08-0810:14 ET | 8-K | 9.01 Financial statements and exhibits | 0001628280-24-035830 |
| 2024-07-1510:50 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-24-079679 |
| 2024-05-2321:12 ET | 8-K | 5.07 Shareholder vote results | 0001628280-24-025011 |
| 2024-05-1421:10 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-24-023287 |
| 2024-05-1411:11 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001628280-24-023056 |
| 2024-05-1410:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-023035 |
| 2024-04-1520:05 ET | DEF 14A | Proxy statementPeriod 2024-05-21 | 0001140361-24-019847 |
| 2024-03-2121:02 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001628280-24-012572 |
| 2024-03-2111:33 ET | 8-K | 7.01 Regulation FD disclosure | 0001628280-24-012367 |
| 2024-03-2110:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-036897 |
| 2024-01-0922:51 ET | 8-K | 7.01 Regulation FD disclosure | 0001628280-24-000874 |
| 2024-01-0812:36 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-002065 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:04 ET. Listed shows no prices and gives no investment advice.